How much would be passed on to consumers remains unknown.

“The impact of this orthopedic device tariff isn’t a straight line,” said David A. Halsey, president of the American Academy of Orthopaedic Surgeons, in an email, adding that the group was working to assess the possible effects.

It is still unclear whether the tariffs will be enacted: Companies have until May to lobby the administration for changes. But on Friday, President Trump ratcheted up the pressure by threatening to levy tariffs on an additional $100 billion in imports, provoking China to respond that it would strike back yet again.

Indeed, stocks of drug manufacturers remained largely unruffled after the unveiling of the list on Tuesday, but by Friday, the major medical device company stocks had dipped along with the overall market. Medtronic shares were 2.7 percent lower for the week, and Zimmer Biomet was down 2.4 percent.

It was unclear whether the tariffs would have a substantial effect on the drug industry, analysts said, even though China is a leading exporter of raw pharmaceutical ingredients. “We don’t see much impact,” Umer Raffat, a pharmaceutical industry analyst for Evercore ISI, said in a note to investors on Tuesday.

That is because many generic drugs that contain Chinese ingredients are manufactured in countries like India, meaning they would not be subject to the tariffs. And brand-name drugs made in the United States are frequently so expensive that the list price often has little connection to the product’s manufacturing cost.

Nevertheless, at least one trade group sounded the alarm on the tariffs, warning that they could exacerbate the already contentious issue of health care costs, just when the Trump administration has pledged to take action to lower drug prices.

“We are concerned that the proposed tariffs may lead to increased costs of manufacturing for generics and biosimilars and thus higher prescription drug prices for patients in the U.S.,” said Jeffrey K. Francer, senior vice president and general counsel at the Association for Accessible Medicines, which represents generic-drug companies. The generic business has been struggling with falling prices even as brand-name drug prices have risen.